Before AI Can Transform Clinical Trials, It Needs More Patient Data

Author(s): Prof. Maddy Parsons

AI is becoming impossible to ignore in discussions about the future of drug development. New tools promise to improve everything from patient recruitment and trial design to biomarker discovery and treatment selection. The expectation is that AI will help us run faster, efficient, and more successful clinical trials.

But there is a danger that we will focus too heavily on the technology itself and not enough on the information that underpins it.

In a recent episode of Hypothesize That!, UCB Head of Global Clinical Development Graham Price and I debated a core hypothesis: Precision medicine will fail to deliver on its future promise because outdated trial frameworks keep us stuck in the past.